DPP4 and chronic kidney disease: Over the last decade, DPP-4 inhibitors have shown a steady uptake in prescription volume, and due to their preferable safety profiles they have been preferably used in T2DM patients with chronic kidney diseases and in those intolerant to adverse effects from other oral antidiabetics8,50.